SC
VIRX

Steven Cohen’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Steven Cohen’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85,714
Closed -$2.16M – 1313
2019
Q3 		$2.16M Buy
85,714
+45,714
+114% +$1.32M 0.01% 581
2019
Q2 		$1.02M Buy
+40,000
New +$1.55M 0.01% 768
2014
Q3 		– Sell
-2,231
Closed -$3.06M – 790
2014
Q2 		$3.06M Buy
+2,231
New +$2.59M 0.02% 520

Other funds holding VIRX

ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Steven Cohen's VIRX Position: Q4 2019 in Review

Steven Cohen sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 85,714 shares — an estimated $2.16M sold.

Steven Cohen first reported a position in VIRX in Q2 2014 and held it in 3 quarters. The position peaked at $3.06M in Q2 2014. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Steven Cohen reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Steven Cohen sold 85,714 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $2.16M.
  • Steven Cohen first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2014 and held it in 3 quarters.
  • Steven Cohen's Viracta Therapeutics, Inc. Common Stock position peaked at $3.06M in Q2 2014.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.